Armijo CCP, Guzmán CJ

Language: Spanish
References: 5
Page: 578-580
PDF size: 1179.64 Kb.

ABSTRACT

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin tumor, often affecting older and immunocompromised individuals. This case involves a 74-year-old male with stage IV MCC presenting as a thigh mass. Diagnosis was confirmed through biopsy and immunohistochemistry. He received avelumab immunotherapy with a partial 90% response in mediastinal lesions, followed by radiotherapy for local control. After 14 cycles of avelumab and 33 radiotherapy sessions, the primary tumor showed a complete response. This case highlights the effectiveness of combining immunotherapy and radiotherapy in metastatic MCC, offering promising disease control and improved survival outcomes in advanced-stage patients.

REFERENCES

1. Juan HY, Khachemoune A. A review of Merkel cell carcinoma. JAAPA. 2023; 36 (11): 11-16.

2. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, SchwartzAM, Henson DE. Merkel cell carcinoma demographics, morphology,and survival based on 3870 cases: a population based study. J CutanPathol. 2010; 37 (1): 20-27.

3. Patel P, Hussain K. Merkel cell carcinoma. Clin Exp Dermatol. 2021; 46: 814-819.

4. Ferini G, Zagardo V, Critelli P, Santacaterina A, Sava S, Harikar MMet al. Introducing radiotherapy in metastatic Merkel cell carcinomapatients with limited progression on avelumab: an effective stepagainst primary and secondary immune resistance? J Pers Med. 2023;13 (5): 841.

5. Green C, Isaksson Mettavainio M, Kjellman C, Ramqvist T, DalianisT, Israelsson P et al. Combined treatment with radiotherapy,chemotherapy and avelumab results in regression of metastaticMerkel cell carcinoma and improvement of associated Lambert-Eatonmyasthenic syndrome: a case report. Oncol Lett. 2022; 24 (5): 393.doi: 10.3892/ol.2022.13513.